Probucol
 | |
| Systematic (IUPAC) name | |
|---|---|
| 4,4'-[propane-2,2-diylbis(thio)]bis(2,6-di-tert-butylphenol) | |
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a611037 |
| Identifiers | |
23288-49-5  | |
| C10AX02 | |
| PubChem | CID 4912 |
| DrugBank |
DB01599 |
| ChemSpider |
4743 |
| UNII |
P3CTH044XJ |
| KEGG |
D00476 |
| ChEBI |
CHEBI:8427  |
| ChEMBL |
CHEMBL608 |
| Synonyms | 2,6-di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenol |
| Chemical data | |
| Formula | C31H48O2S2 |
| 516.844 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Probucol is an anti-hyperlipidemic drug[1] initially developed in the treatment of coronary artery disease.
However, clinical trials were stopped after it was found that it may lower HDL in patients with a previous history of heart disease.
Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity. Probucol is associated with QT interval prolongation.
Mechanism
Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption.[2] Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.
It is believed to act at ABCA1.[3]
It also lowers levels of HDL.[4]
References
- ↑ Yamamoto A (December 2008). "A Uniqe Antilipidemic Drug - Probucol". J. Atheroscler. Thromb. 15 (6): 304–5. doi:10.5551/jat.E621. PMID 19075491.
- ↑ "Probucol. Drugs.com web site.
- ↑ Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH (December 2004). "Probucol inhibits ABCA1-mediated cellular lipid efflux". Arterioscler. Thromb. Vasc. Biol. 24 (12): 2345–50. doi:10.1161/01.ATV.0000148706.15947.8a. PMID 15514211.
- ↑ Miida T, Seino U, Miyazaki O et al. (October 2008). "Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling". Atherosclerosis 200 (2): 329–35. doi:10.1016/j.atherosclerosis.2007.12.031. PMID 18279878.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||